An open‐label, crossover study of a new phosphate‐binding agent in haemodialysis patients: ferric citrate | Zendy

WuChang Yang | Zendy; ChweiShiun Yang | Zendy; ChunChen Hou | Zendy; TsaiHung Wu | Zendy; Eric W. Young | Zendy; Chen H. Hsu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

An open‐label, crossover study of a new phosphate‐binding agent in haemodialysis patients: ferric citrate

Author(s) -

WuChang Yang,

ChweiShiun Yang,

ChunChen Hou,

TsaiHung Wu,

Eric W. Young,

Chen H. Hsu

Publication year - 2002

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/17.2.265

Subject(s) - medicine , phosphate binder , hemodialysis , calcium , secondary hyperparathyroidism , crossover study , ferric , hyperparathyroidism , washout , phosphate , dialysis , endocrinology , calcium carbonate , parathyroid hormone , biochemistry , chemistry , hyperphosphatemia , inorganic chemistry , alternative medicine , organic chemistry , pathology , placebo

Hyperphosphataemia contributes to secondary hyperparathyroidism and renal osteodystrophy in patients with end-stage renal disease (ESRD). Calcium salts are widely employed to bind dietary phosphate (P) but they may promote positive net calcium balance and metastatic calcification. We recently reported that ferric compounds bind intestinal phosphate in studies of normal and azotemic rats.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research